BackgroundIn 2014, the World Health Assembly approved the World Health Organization's (WHO) Post-2015 Global TB Strategy,
which aims to end the global TB epidemic by 2035 with an associated 95% decline in TB deaths, and a 90% decline in
TB incidence. This strategy represents a unique and unprecedented opportunity to improve tuberculosis control inboth high and low-incidence countries. TB control efforts will have to be dramatically intensified to meet the bold
new goals. Innovations in care and prevention of TB have become part of a three pillar strategy that expands wellbeyond the traditional TB approach. A synergy of interventions from early case detection, to addressing theemergence of M(X)DR-TB needs to be addressed in order to achieve these targets.
The immensity of the challenges posed by the increasing emergence and uncontrolled spread of drug-resistant formsof TB underlines the failure of the status quo. Too many TB cases are neither diagnosed nor treated in time to avoid
onward transmission. The treatment of MDR-TB patients using only existing anti-TB drugs has created an urgent
unmet medical need. Low coverage of drug susceptibility testing (DST) in many countries and detection of drug
resistance remains a major challenge. According to the WHO 2012 report only 94,000 cases of drug-resistant TB wereidentified. This indicates that the vast majority of patients went undiagnosed and could not be treated according tointernationally recognized standards. The need for accurate diagnosis of TB and rapid detection of drug-resistanceare critical to ensure timely initiation of treatment. The TB community has waited a long time for new MDR-TB
medications and to ensure patients do not develop resistance to the new drugs better TB control practices have tobe adapted.
This year the TB expert’s community meeting will be “Addressing the many faces of TB prevention in Asia”.

Overarching goal: Provide a forum for international discussion and development of a consensus statement of actionneeded to achieve unified and consistent standards for TB screening and prevention from the Asian TB experts
community.
Objectives:
1. Create a forum for the presentation and discussion of:
A. The importance of early diagnosis of tuberculosis including universal drug-susceptibility testing, andsystematic screening of contacts and high-risk groups
B. Treatment of all people with Tuberculosis including drug resistant tuberculosis and patient support
2. Determine a regional best practise approach for the adaption on new LTBI guidelines.

Format:actionSymposium combining presentations and breakout discussions leading to concrete common statement ofDisclamer: This meeting is made possible by the provision of an unrestricted grant to Stop TB Japan by Otsuka,
Sanofi- Aventis and Qiagen.

ストップ結核パートナーシップ日本 〒101-0061 東京都千代田区三崎町 1-3-12 結核予防会内
S t o p T B P a r t ne r sh ip J a p a n 1 - 3 - 1 2 , Mi s a k i - ch o , C h iy o d a - k u, T o k y o , 1 0 1 - 0 0 6 1 , J A P A N
Tel 03 5282 3010 Fax 03 5980 8267
www.stoptb.jp
info@stoptb.jp

Date: August 7th – 9th 2015
Location: Bali, Indonesia“Addressing the Many faces of TB Prevention in Asia”
Chaired by: Toru Mori, MD, PhD, Executive Representative, Stop TB Partnership Japan, Director Emeritus, ResearchInstitute Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)
Co- Chair: Erlina Burhan, MD?

Friday 7th August
19:00- 21:30

Welcome reception Canapés and Cocktails

Saturday 8th August
09:00 – 09:15

Location
TBD

TopicSpeaker Name

Welcome, introductions and review of the agenda,

Toru Mori, MD

Introductions
09:15 – 10:00

WHO – Keynote speech

Mario Raviglione or

Post- 2015 TB elimination strategy- A vision for

Nobuyuki Nishikiori orAsia.
Alberto Matteelli
10:00- 10:30

Preventing TB Disease: Improving the Diagnosis andChuck Daley, MD

Treatment of TB Infection
10:30- 11:00

Break11:00-11:30

Presentation from Stop TB partnership

11:30-12:00

Drug resistant TB

12:00-12:30

Experiences in Indonesia: Optimization of the newLucica Ditiu, MD
Ernesto Jaramillo, MD
Christina Widaningrum, MD

MDR drug regiment

ストップ結核パートナーシップ日本 〒101-0061 東京都千代田区三崎町 1-3-12 結核予防会内
S t o p T B P a r t ne r sh ip J a p a n 1 - 3 - 1 2 , Mi s a k i - ch o , C h iy o d a - k u, T o k y o , 1 0 1 - 0 0 6 1 , J A P A N
Tel 03 5282 3010 Fax 03 5980 8267
www.stoptb.jp
info@stoptb.jp

212:30- 13:30

Lunch

13:30-14:00

Introduction of new drug regiments in high M(X)DR

Rosalind G. Vianzon, MDcountries
14:00-14:30

Putting Bi-directional TB and Diabetes screening

Dyah Erti Mustikawati

into action
14:30-15:00

Rifapentine in Asia

15:00-15:30

TBA
Break

15:30-16:00

China:

16:00-16:30

India ?

16:30-17:00

Japan ?

Soumya Swaminathan, MDTBA

Sunday 9th August
9:00-9:15
9:15-9:30
9:30- 10:30

Welcome and review of the day 1 program,
Introduction to structured discussion
Structured Discussion

Whole group10:30-11:00
11:00-12:00

BreakGroup discussion & presentations

Whole group

12:00-12:15
12:15-12:30

Summary and wrap up
Closing speech

Toru Mori, MD

ストップ結核パートナーシップ日本 〒101-0061 東京都千代田区三崎町 1-3-12 結核予防会内
S t o p T B P a r t ne r sh ip J a p a n 1 - 3 - 1 2 , Mi s a k i - ch o , C h iy o d a - k u, T o k y o , 1 0 1 - 0 0 6 1 , J A P A N
Tel 03 5282 3010 Fax 03 5980 8267
www.stoptb.jp
info@stoptb.jp